Interim results presented at EASL from PROVE 1 clinical trial of investigational drug telaprevir in patients with genotype 1 hepatitis C

被引：8
|
作者：
Lang, Les
机构：
来源：
GASTROENTEROLOGY | 2007年 / 132卷 / 07期
关键词：
D O I：
10.1053/j.gastro.2007.04.063
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：2283 / 2284
页数：2
相关论文
共 50 条
  • [1] Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients
    Burney, Tabinda
    Dusheiko, Geoffrey
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2011, 9 (02) : 151 - 160
  • [2] Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection
    Cunningham, Morven
    Foster, Graham R.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2012, 5 (02) : 139 - 151
  • [3] Cost-Effectiveness of Telaprevir in Patients with Genotype 1 Hepatitis C in Australia
    Warren, Emma
    Wright, Alison
    Jones, Brandon
    VALUE IN HEALTH, 2014, 17 (08) : 792 - 800
  • [4] Drug Eruptions Induced by Telaprevir in Patients With Chronic Hepatitis C Virus Genotype 1 Infection: Prospective Study
    Toro Montecinos, M.
    Carrascosa Carrillo, J. M.
    Vilavella Rius, M.
    Bielsa Marsol, I.
    Plana Pla, A.
    Morillas Cunill, R.
    Planas Vila, R.
    Masnou Ridaura, H.
    Lopez Escartin, D.
    Ferrandiz Foraster, C.
    ACTAS DERMO-SIFILIOGRAFICAS, 2015, 106 (03): : 219 - 225
  • [5] Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV A Randomized Trial
    Sulkowski, Mark S.
    Sherman, Kenneth E.
    Dieterich, Douglas T.
    Bsharat, Mohammad
    Mahnke, Lisa
    Rockstroh, Juergen K.
    Gharakhanian, Shahin
    McCallister, Scott
    Henshaw, Joshua
    Girard, Pierre-Marie
    Adiwijaya, Bambang
    Garg, Varun
    Rubin, Raymond A.
    Adda, Nathalie
    Soriano, Vincent
    ANNALS OF INTERNAL MEDICINE, 2013, 159 (02) : 86 - W35
  • [6] Telaprevir for the treatment of genotype 1 chronic hepatitis C virus
    Laffman-Johnson, Elise
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (02) : 159 - 159
  • [7] Comparative effectiveness and safety of boceprever and telaprevir for chronic genotype 1 hepatitis C in a community setting: interim analysis
    Loucks, Aimee R.
    Chan, Jim
    Hui, Rita L.
    Spence, Michele M.
    Szpakowski, Jean-Luc
    HEPATOLOGY, 2013, 58 : 1143A - 1144A
  • [8] FIBROSIS STAGING PREDICTS VIROLOGICAL RESPONSE IN HEPATITIS C GENOTYPE 1 PATIENTS: INTERIM DATA FROM THE PROPHESYS TRIAL
    Horban, A.
    Rodriguez-Torres, M.
    Cheinquer, H.
    Curescu, M.
    Pol, S.
    Silva, G. F.
    Orlandini, A.
    Lee, S. S.
    Ascione, A.
    Messinger, D.
    Tatsch, F.
    Ferenci, P.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S175 - S176
  • [9] Healthcare Utilization in Phase 3 Telaprevir Clinical Trials for the Treatment of Genotype 1 Chronic Hepatitis C Patients
    Werther, Winifred
    Aggarwal, Jyoti
    Goss, Thomas F.
    Vera-Llonch, Montserrat
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 104 - 105
  • [10] Triple Therapy Utilizing Telaprevir for Incarcerated Patients With Genotype 1 Chronic Hepatitis C Infection: Initial Results From a Pilot Study
    Rice, John P.
    Carlson, Amanda
    Burnett, David
    Cervantes, Lisa
    Striker, Rob
    Lucey, Michael R.
    GASTROENTEROLOGY, 2014, 146 (05) : S921 - S921
12345